Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
Síntesis orgánica, síntesis a medida, desarrollo de procesos y apoyo al escalado para proyectos químicos avanzados.
Tecnologías de síntesis y análisis para moléculas complejas.
CHEMOS es un CDMO impulsado por la síntesis, centrado en síntesis orgánica, síntesis a medida, desarrollo de rutas, desarrollo de procesos, apoyo al escalado y soporte analítico. Trabajamos con materiales de administración avanzada de fármacos, bloques de bioconjugación, quelantes radiofarmacéuticos, intermediarios PROTAC y compuestos orgánicos especializados.
Noticias, perspectivas y actualizaciones de CHEMOS.
FDA announced on July 16, 2026 that Lipfendra (enlicitide) was approved to be used with diet and exercise to reduce LDL-C in adults with high cholesterol or heterozygous familial hypercholesterolemia. FDA also states that Lipfendra is a tablet taken by mouth once daily and is the first oral therapy that blocks PCSK9.
Leer másThe key correction is that the ACS Organic Process Research & Development paper describes LUNA18 (paluratide) through a liquid-phase peptide synthesis process, not a simple SPPS plus three-fragment route. The paper’s abstract says the authors departed from conventional solid-phase peptide synthesis and developed an LPPS process for an N-alkyl-rich cyclic undecapeptide KRAS inhibitor.
Leer más
The reported inclisiran architecture illustrates why an siRNA conjugate cannot be reduced to a sequence plus a targeting ligand. Descriptions of that architecture place a triantennary N-acetylgalactosamine (GalNAc) unit at the sense-strand terminus, combine 2'-fluoro and 2'-O-methyl ribose substitutions with terminal phosphorothioate linkages, and rely on the antisense strand for RNA-induced silencing complex (RISC) loading. Each element addresses a different constraint: cell uptake, nuclease exposure, strand handling, or intracellular recognition.
Desde la evaluación temprana de una ruta hasta el desarrollo de procesos y el escalado, CHEMOS ofrece soporte de síntesis a medida basado en experiencia de I+D y base productiva.
